UK’s Government’s Medicines & Healthcare products Regulatory Agency (MHRA) spends close to $2million on an Artificial Intelligence to monitor “Medicines & Healthcare products Regulatory Agency”. If this isn’t alarming, I don’t know what is. But I know there’s more to the story.
The MHRA urgently seeks an Artificial Intelligence (AI) software tool to process the expected high volume of Covid-19 vaccine Adverse Drug Reaction (ADRs) and ensure that no details from the ADRs’ reaction text are missed.
Thanks Graham Pick for the tip!
The acquisition document further provides this explanation:
“For reasons of extreme urgency under Regulation 32(2)(c) related to the release of a Covid-19 vaccine MHRA have accelerated the sourcing and implementation of a vaccine specific AI tool.
Strictly necessary — it is not possible to retrofit the MHRA’s legacy systems to handle the volume of ADRs that will be generated by a Covid-19 vaccine. Therefore, if the MHRA does not implement the AI tool, it will be unable to process these ADRs effectively. This will hinder its ability to rapidly identify any potential safety issues with the Covid-19 vaccine and represents a direct threat to patient life and public health.
Reasons of extreme urgency — the MHRA recognises that its planned procurement process for the SafetyConnect programme, including the AI tool, would not have concluded by vaccine launch. Leading to a inability to effectively monitor adverse reactions to a Covid-19 vaccine.
Events unforeseeable — the Covid-19 crisis is novel and developments in the search of a Covid-19 vaccine have not followed any predictable pattern so far.”
Beneficiary of this contract is a company named Genpact, part of a larger multi-industry group with the same name. Genpact also does Facebook moderation, which gives it access to Facebook data!
Genpact CEO is close to our old friends from WEF, of course
Here he supports using military to distribute the vaccine that will then provide work for his company:
He seems to applaud a Biden victory in the US presidentials. :
This Tyger dude basically has all the traits and inclinations of the elite mafia that set up Covidiocracy as the new business and live-stock management model for the whole world.
Genpact has acquired 23 companies, including 10 in the last 5 years. A total of 8 acquisitions came from private equity firms. Genpact’s largest acquisition to date was in 2011, when it acquired Headstrong for $550M. Genpact has acquired in 11 different US states, and 5 countries. The Company’s most targeted sectors include information technology (28%) and software (28%). – Mergr
We are funded solely by our most generous readers and we want to keep this way. Help SILVIEW.media deliver more, better, faster, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
This life-changing information has been sitting on UK Government’s website for over 15 months now. People find out about it from us, while their officials keep yapping 24/7 about an infection we can’t test for and a virus that’s never been properly isolated and purified in a lab as per Koch’s Postulate. Of course, this plan is not limited to UK, it’s global. Looks like democracy is as real as Rona, your informed consent matters and governments care.
The Fourth Industrial Revolution is not a buzzword, it’s official policy in every state controlled by the World Bank /IMF / Rothschild dynasty. It’s been so for long now. And The Great Reset gives you the map for it, in that Technocrat language that is translated to functional-illiterate sheeple as whatever they need to hear to stay obedient, while the sheeple-herders get actual live-stock management advice.
Regulation for the Fourth Industrial Revolution
Published 11 June 2019
Presented to Parliament by the Secretary of State for Business, Energy and Industrial Strategy by Command of Her Majesty
The world is changing faster than ever. New technology is creating new industries, changing existing ones and transforming the way things are made. We need a more agile approach to regulation, that supports innovation while protecting citizens and the environment.
We are a nation of innovators. Throughout our history we have seized the opportunities to create a better future for ourselves. In the First Industrial Revolution, British engineer Thomas Savery’s pump paved the way for industrial use of steam power. In the second, British scientist Michael Faraday’s electromagnetic rotary devices formed the basis for practical electricity use. In the third, British computer scientist Tim Berners-Lee invented the world wide web.
Technological breakthroughs in areas from artificial intelligence to biotechnologies are now heralding a Fourth Industrial Revolution, with the power to reshape almost every sector in every country. Our Industrial Strategy positions the UK to make the most of this global transformation.
Our regulatory system is second to none, as recognised by the Organisation for Economic Cooperation and Development’s Regulatory Policy Outlook in 2018. It protects citizens and enables business to thrive. Together with our global research prowess, world-class universities and open, competitive markets, it attracts firms to innovate and invest in the UK. As the Fourth Industrial Revolution changes the way we live and work, it is vital that our regulatory system keeps pace.
This white paper sets out our plan to maintain our world-leading regulatory system in this period of rapid technological change. We will support and stimulate new products, services and business models, with greater space for experimentation. We will uphold safeguards for people and the environment and engage the public in how innovation is regulated. And we will maintain the stable, proportionate regulatory approach the UK is rightly known for.
Our openness to technology and innovation continues as we leave the European Union.
This white paper is our plan to secure our success.
We need to take action to maintain our world-beating regulatory system and realise the potential of the Fourth Industrial Revolution.
The Fourth Industrial Revolution
The Fourth Industrial Revolution is of a scale, speed and complexity that is unprecedented. It is characterised by a fusion of technologies – such as artificial intelligence, gene editing and advanced robotics – that is blurring the lines between the physical, digital and biological worlds. It will disrupt nearly every industry in every country, creating new opportunities and challenges for people, places and businesses to which we must respond.
Our modern Industrial Strategy seeks to put the UK at the crest of this global wave of technological innovation, bringing the benefits to business and consumers alike. Our foundations are strong. The UK ranks in the top 5 in the Global Innovation Index1. We are a global leader in science and research and home to 4 of the top 10 universities in the world2. We have a thriving start-up environment and are home to many of the world’s most R&D-intensive businesses. We develop and attract some of the most talented people in the world.
We want to build on our strengths in developing and deploying ideas to become the world’s most innovative economy. We want to raise our total investment in R&D to 2.4% of GDP by 2027, the biggest increase on record. We have set 4 Grand Challenges for the UK government and wider economy to seize the opportunities presented by the Fourth Industrial Revolution.
The Industrial Strategy Grand Challenges
We will put the UK at the forefront of the artificial intelligence and data revolution.
We will maximise the advantages for UK industry of the shift to clean growth.
We will become a world leader in shaping the future of mobility.
We will harness the power of innovation to help meet the needs of an ageing society.
Our regulatory system is a national asset. We are ranked 9th among 190 economies for the ease of doing business in the UK3, with the quality of our regulatory practices given the highest overall country score by the Organisation for Economic Co-operation and Development (OECD)4. We protect the natural environment and ensure the safety and employment rights of citizens. We also provide the certainty needed for businesses to thrive.
The Fourth Industrial Revolution presents challenges for regulatory systems across the globe, as they struggle to keep pace with rapid, complex technological innovation. In our Industrial Strategy, we committed to develop an agile regulatory approach that supports innovation and protects citizens and the environment. We need to act now to maintain our world-beating regulatory system in this period of transformational change.
We need to reshape our regulatory approach so that it supports and stimulates innovation that benefits citizens and the economy. At present, only 29% of businesses believe that the government’s approach to regulation facilitates innovative products and services being efficiently brought to market 9. The need for reform is urgent: 92% of businesses from a range of sectors think they will feel a negative impact if regulators don’t evolve to keep pace with disruptive change in the next 2 to 3 years10.
Other countries are rapidly reforming their regulatory environments to support future innovation, with Nesta describing these anticipatory approaches as ‘an increasingly important source of competitive advantage in the global economy’11. By taking an anticipatory approach we can give people faster access to innovations that can transform their lives and attract the ideas, talent and investment to the UK that will drive our future prosperity.
We are turning things round. The Financial Conduct Authority’s regulatory sandbox has kick-started a wave of regulator-led initiatives to support new products and services to come to market and been widely emulated across the globe. Our Regulators’ Pioneer Fund is accelerating the change, with £10 million invested in 15 projects to support technologies from autonomous shipping to virtual lawyers. We have established a partnership with the World Economic Forum to shape the global governance of technological innovation.
we need to be on the front foot in reforming regulation in response to technological innovation
we need to ensure that our regulatory system is sufficiently flexible and outcomes-focused to enable innovation to thrive
we need to enable greater experimentation, testing and trialling of innovations under regulatory supervision
we need to support innovators to navigate the regulatory landscape and comply with regulation
we need to build dialogue with society and industry on how technological innovation should be regulated
we need to work with partners across the globe to reduce regulatory barriers to trade in innovative products and services
This white paper sets out our plan to tackle these 6 challenges and seize the opportunity presented by the Fourth Industrial Revolution. We want to lead the world in innovation-friendly regulation that supports the emergence of new products, services and business models for the benefit of all. The white paper will be matched later this year with papers describing how we will modernise consumer and competition regulation in response to the transformation in our economy.
Supporting the emergence of smart systems
Our energy system is changing rapidly. There is more low carbon generation, such as power from solar and wind, which produces different amounts of electricity depending on the weather. It is increasingly decentralised, with generation and batteries located in or near people’s homes and businesses. New technologies such as electricity storage, smart heating controls and electric vehicles are emerging which can be used to help balance the electricity system. However, our regulatory system was not developed with these new technologies in mind.
As laid out in the Smart Systems and Flexibility Plan, developed jointly with the energy regulator Ofgem, we are working to develop a best in class regulatory framework that supports these innovations. We are working with industry to reform markets, legislation, licences, codes and standards.
The drive towards a smart and flexible energy system is an important tenet of the government’s Clean Growth and Industrial Strategies. The changes promise to provide significant public benefits, from lower energy bills to cleaner air and lower carbon emissions. By 2050, a smarter and more flexible system could save the UK £17-40 billion.
Accelerating the introduction of self-driving vehicles
The Centre for Connected and Autonomous Vehicles (CCAV) is overseeing a groundbreaking programme to prepare the UK’s regulatory framework for self-driving vehicles ahead of their introduction on UK roads. It has developed an open regulatory approach that safeguards citizens and supports the development of the technology as it evolves.
This includes the recently updated world-leading Code of Practice for testing automated vehicles. Testing any level of automated vehicles on public roads is possible, provided they comply with the law, including having a driver, in or out of the vehicle, a roadworthy vehicle, and appropriate insurance. The recent update to the Code announced that the government would introduce an application process for more advanced trials. This will facilitate the development of the technology, without the need for repeated changes to regulation.
CCAV is leading the charge in considering the wider implications of the introduction of self-driving vehicles. It has introduced legislation to insure the use of self-driving vehicles through the Automated and Electric Vehicles Act 2018, so that victims of collisions get quick and easy access to compensation. It has asked the Law Commission of England and Wales and the Scottish Law Commission to undertake a joint regulatory review to identify further legal obstacles to the widespread introduction of self-driving vehicles. This project is consulting widely and will provide a final report in 2021.
CCAV is also working with the British Standards Institution to deliver a programme of standards to help accelerate development and deployment of self-driving vehicles. The programme seeks to address public safety and reliability concerns and supports the UK’s reputation as a centre of excellence for vehicle testing, design and manufacturing.
CCAV’s programme has helped to put the UK at the forefront of this emerging industry and, with the Department for Transport, given the UK lasting influence in international debates on the regulation of automated vehicles.
We will create an outcome-focused, flexible regulatory system that enables innovation to thrive while protecting citizens and the environment. We will match this with clarity for business through better use of regulatory guidance, codes of practice and industry standards.
We will pilot an innovation test so that the impact of legislation on innovation is considered as we:
develop and assess policy options
consult and engage on policy proposals
design, introduce and implement legislation
monitor, evaluate and review legislation
We will encourage policymakers to consider the governance of innovation in a holistic way, noting the role that alternatives to regulation can play in providing government, citizens and businesses with assurance. We will encourage policymakers to reflect on when the right time is to introduce regulation21 .
Our approach will encourage policymakers to focus on real-world outcomes, with legislation that provides flexibility for experimentation and adaptation. Prescriptive regulatory requirements would only be set out in legislation where necessary to provide important protections. Where possible, alternative approaches such as statutory guidance will set out requirements so that as technology changes the system can respond in a timely and flexible manner.
We will develop tools for policymakers to support them to consider these issues; we will also develop improved analytical methods to capture the impact of regulation on innovation. During the pilot, we will invite the Regulatory Policy Committee to scrutinise the application of the innovation test, to ensure that innovators have confidence in how government is developing significant new regulatory legislation.
Making the UK the safest place in the world to be online
The internet is a powerful force for good. Combined with new technologies such as artificial intelligence, it is changing society perhaps more than any previous technological revolution – growing the economy, making us more productive, and raising living standards.
Alongside these new opportunities come new challenges and risks. The internet can be used to spread terrorist material; it can be a tool for abuse and bullying; and it can be used to undermine civil discourse, objective news and intellectual property. As set out in our Digital Charter, we are committed to making the UK both the safest place to be online and the best place to start and grow a digital business.
In April, the Department for Digital, Culture, Media and Sport and the Home Office published a white paper to tackle a range of both legal and illegal harms, from cyberbullying to online child sexual exploitation. In keeping with our ambition to lead the world in innovation-friendly regulation that encourages the tech sector and provides stability for businesses, the white paper sets out an outcomes-focused legislative approach that will support future technological change.
Realising the power of financial technologies
From AI to blockchain, data-driven financial technologies (FinTech) are changing the way that we bank, invest, insure and even pay for things. The UK’s FinTech sector is booming, underpinned by our world-leading financial services sector and thriving tech scene.
In 2016, the Financial Conduct Authority seized the initiative to support this emerging industry by establishing the world’s first ‘regulatory sandbox’: a safe space where firms can work with the regulator to trial innovative products, services and business models with consumers without having to meet all the usual requirements for compliance. Since its establishment, the sandbox has received more than 3 times as many applications than places available. Access to the sandbox has helped reduce the time and cost of getting innovative ideas to market (in the first year, 90% of firms progressed towards wider market launch) and improve access to finance (40% received investment during or following their sandbox tests).
FinTech firm Asset Hedge introduced a web-based platform offering forex options to assist small businesses and individuals to protect against losses incurred because of currency fluctuations. They successfully completed the sandbox programme to become a fully regulated company. Assure Hedge founder and chief executive Barry McCarthy said:
“We have effectively been given the same regulation that large banks have, so it really allows us to compete with the big players.”
It’s not just business that benefits. Consumers benefit from new products which have better safeguards built in up front, while the regulator benefits from greater insight into technological innovation. The model has been emulated by more than 20 countries across the globe and translated to sectors from health to transport.
From smart shipping to AI-powered legal services
The Regulators’ Pioneer Fund is backing the Future of Mobility and AI and Data Grand Challenges through ground breaking projects to enable technologies from smart shipping to AI-powered legal services.
The Solicitors Regulation Authority has already taken steps to facilitate innovation in the legal industry, inviting firms to develop new business models in a controlled way. The Regulators’ Pioneer Fund investment will enable the Solicitors Regulation Authority to work with the innovation foundation Nesta to accelerate ethical AI-powered innovations, with a focus on legal services for small businesses and consumers where AI and automation can have transformative impact.
Paul Philip, Chief Executive of the Solicitors Regulation Authority, said:
“Smart use of technology could help tackle the problem that far too many people struggle to access expert legal advice. It will help us further build on our work to encourage new ways of delivering legal services, benefiting both the public and small business.”
In the Maritime and Coastguard Agency, the Regulators’ Pioneer Fund investment will create the Maritime Autonomy Regulation Lab (MAR Lab) to bring together industry specialists, academics and government to pioneer new regulatory approaches and make data available to the emerging smart shipping industry.
The project will inform UK legislation for a domestic framework for autonomous vessels to attract international business and support and promote testing in the UK’s territorial waters. It will also support government efforts to establish a new proactive and adaptive international regulatory framework for autonomous vessels at the International Maritime Organisation.
Supporting the revolution in life sciences
New discoveries and the application of new technologies mean we can diagnose illnesses earlier and more accurately, create new treatments and ensure existing ones are more effective.
The UK is extraordinarily well placed to play a leading role in this revolution in the life sciences, with strengths in innovation, research, healthcare and business. To support these innovations to come to market, the Medicines and Healthcare Products Regulatory Agency’s (MHRA) Innovation Office provides a single point of access to regulatory advice on the development of innovative medicines, medical devices or manufacturing processes. The service has grown in popularity since its inception in 2013, receiving 190 enquiries in 2018.
The service helps to make regulatory information clear and accessible to those who are working on innovative research, supporting a key goal in the second Life Sciences Sector Deal to ensure the UK remains one of the best places in the world to develop life sciences projects, to protect health and improve lives.
The service has helped secure significant investments into the UK life sciences industry. John Parker, Director at AstraZeneca said:
“We genuinely believe that having easy access to MHRA in this manner provides a real competitive advantage to UK based companies”
In the Life Sciences Sector Deal, the MHRA committed to engage with industry to understand how it can further develop its offer by the end of 2019.
Entrepreneurs and innovative firms should be able to find their way through the UK’s regulatory landscape with ease and receive timely, joined-up feedback on novel propositions.
We will consult on a digital Regulation Navigator for businesses to help them find their way through the regulatory landscape and engage with the right regulators at the right time on their proposals. We will ensure that this is integrated with action to enhance the government’s digital offer to business in areas such as tax, grants, trade and investment, and build awareness of the available offer.
Initiatives such as the Financial Conduct Authority’s regulatory sandbox have helped reduce the time and cost of bringing new products and services to market and enabled businesses to win contracts and secure access to finance. We are funding greater investment in specialist regulatory advice services for innovators through our Regulators’ Pioneer Fund, to ensure that innovators who are developing novel proposals with potential for wider economic, societal or environmental benefit are supported to do so.
Leading the public dialogue on mitochondrial replacement treatment
Mitochondria are present in almost all human cells and generate the majority of their energy supply. Unhealthy mitochondria can cause genetic disorders known as mitochondrial disease, which can have devastating effects on the families that carry them. For many patients with mitochondrial diseases, preventing the transmission of the disease to their children is a key concern.
In 2012, the Human Fertilisation and Embryology Authority undertook a sustained engagement programme to determine public acceptability of the use of mitochondrial replacement treatment, characterised in the media as ‘3 parent babies’. The programme included a breadth of engagement tools, including workshops, a public survey, open meetings and focus groups. It invited trusted scientific figures to take part in the debate.
The regulator found that despite certain ethical concerns there was general support for permitting mitochondria replacement in the UK, so long as it is safe enough to offer in a treatment setting and is done so within a regulatory framework. Following legislation, in 2017 the UK became the first country in the world to license mitochondrial donation techniques to allow women who carry the risk of serious mitochondrial disease to avoid passing it onto their children.
We want innovators and the public to have confidence in the UK’s regulatory regime. We will build dialogue with society and industry on how technological innovation should be regulated.
We will ask the Regulatory Horizons Council to identify priorities for greater public engagement on regulation of innovation. For example, where technologies pose complex ethical or moral considerations greater public engagement may be appropriate to shape government thinking on appropriate regulatory frameworks. Government departments and regulators will continue to lead public engagement on their policies, working with expert bodies such as the Centre for Data Ethics and Innovation.
As part of its role, the Better Regulation Executive will provide support, advice and share best practice with policymakers and regulators on public engagement techniques to support appropriate regulation of technological innovation, working with partners such as Sciencewise. The Better Regulation Executive will build capability in novel and creative public engagement techniques that go beyond public consultation in this important area.
Engaging the public on regulation of drones
Drone technology is advancing rapidly with the potential to perform critical services in everyday life – from transporting urgent medical supplies to bridge inspection and repair. UK cities and regions need to consider what they want the future of drone applications to look like. PwC estimates that by 2030 drone use could increase UK GDP by £42 billion.
With support from the government’s Industrial Strategy Challenge Fund, the innovation foundation Nesta funded public use analysis of drones in 5 cities for activities from inspecting burning buildings to traffic incident response. It worked with the government and the Civil Aviation Authority and convened local stakeholders to assess demand and identified the technical, economic and regulatory success factors for safe drone deployment at scale in cities.
The programme has concluded that there is demand for drones, which can fulfil socially beneficial goals. However, there are regulatory challenges that need to be solved – from how to deploy drones over long distances to what is publicly acceptable in terms of noise, privacy, safety and other issues. These issues are being considered as part of the Department for Transport’s Aviation Strategy 2050 green paper, looking at how a flexible regulatory framework can be established to support transport innovation under the Future of Mobility Grand Challenge and beyond.
Setting global standards on smart cities
Many cities face challenges in ensuring sustainable growth, with issues ranging from provision of water and energy to management of healthcare and transport. A range of innovation is emerging to create the smart cities of the future.
The British Standards Institution has developed a ground-breaking series of standards on smart cities, in collaboration with the Future Cities Catapult. International recognition of the smart cities standards programme contributes to the UK’s reputation in advanced urban services and helps shape the global market in line with established UK good practice.
Downloaded in over 60 countries, UK smart city standards are being adopted as international standards. In China, the world’s largest smart cities market, the British Standards Institution has set up a cooperation agreement on smart cities with the Standards Administration of China to develop a common approach to smart cities between UK and Chinese cities and companies.
This white paper is our long-term strategy for maintaining our world-leading regulatory environment as we enter the Fourth Industrial Revolution. The Ministerial Working Group on Future Regulation will drive its delivery, supported by the Better Regulation Executive.
The white paper is a plan for the whole of government, shaping how we will regulate in areas from healthcare to transport. We want to give businesses confidence to innovate and invest in the UK and give citizens confidence in our protections.
In addressing these issues we respect the devolution settlements with Scotland, Wales and Northern Ireland. We will work with our partners in the devolved administrations and local authorities to share our innovation-enabling approach and ensure that every part of the UK benefits from the Fourth Industrial Revolution.
Summary of commitments
Facing the future
We will establish a Regulatory Horizons Council to identify the implications of technological innovation and advise the government on regulatory reform needed to support its rapid and safe introduction.
The Council will prepare a regular report on innovation across the economy, with recommendations on priorities for regulatory reform to put the UK at the forefront of the industries of the future.
The Ministerial Working Group on Future Regulation, chaired by the Business Secretary, will oversee the government response to the Council’s recommendations.
Focusing on outcomes
We will pilot an innovation test so that the impact of legislation on innovation is considered during the development of policy, introduction and implementation of legislation and its evaluation and review.
During the pilot, we will invite the Regulatory Policy Committee to scrutinise the application of the innovation test, to ensure that innovators have confidence in how government is developing new legislation.
We will promote new ways to trigger when post-implementation reviews of legislation are undertaken to ensure that legislation does not inadvertently ‘lock in’ outdated technologies or approaches.
We will develop tools for regulators to support them to review their guidance, codes of practice and other regulatory mechanisms to ensure that they provide flexibility for those businesses that want to innovate, while ensuring a clear route to compliance.
We will support business, policymakers and regulators to make effective use of standards where appropriate as a complement to legislation.
We will invite the Office for Product Safety and Standards, British Standards Institution, National Physical Laboratory and UK Accreditation Service to set out their vision for how the development and review of standards should evolve as we enter the Fourth Industrial Revolution.
We will examine the case for expanding the Regulators’ Pioneer Fund in future to help regulators to keep pace with technological innovation and enable the emergence of new products, services and business models.
We will examine the case for extending the Regulators’ Pioneer Fund to local authorities in future, in order to help them support greater testing and trialling of innovations in their area.
We have established a Regulators’ Innovation Network to help foster a culture of experimentation across regulators and share best practice.
We will ask regulators to go further to evaluate the impact of their initiatives on innovation and consider whether to commence statutory reporting requirements for regulators on the impact of the economic growth duty.
We will survey innovators and regulators to identify data that could be shared to enable disruptors to enter markets and deliver better outcomes for all.
We will consult on a digital Regulation Navigator for businesses to help them find their way through the regulatory landscape and engage with the right regulators at the right time on their proposals.
We have financed greater investment in specialist regulatory advice services for innovators through the Regulators’ Pioneer Fund.
We will scope and consult on measures to enhance co-ordination between regulators to ensure that innovations are guided smoothly through the system.
We will consider whether the Regulation Navigator should include functions for businesses to raise where rules or processes are inappropriately constraining innovation, so that regulators can review, clarify and potentially amend their approach.
We will invite regulators to develop metrics on the service that they provide to innovators.
We will ensure that data from specialist advice services is fed into the Regulatory Horizons Council, so that it can advise on where regulatory change or additional investment may be needed to enable innovation to thrive.
We will ask the Regulatory Horizons Council to identify priorities for greater public engagement on regulation of innovation.
We will provide support, advice and share best practice with policymakers and regulators on public engagement techniques to support appropriate regulation of technological innovation.
We will encourage regulators to build public dialogue into experimentation initiatives (such as those financed through the Regulators’ Pioneer Fund), so that public views are considered as new products, services and business models are trialled.
Leading the world
We have established a partnership with the World Economic Forum Centre for the Fourth Industrial Revolution in San Francisco to develop regulatory approaches for new technologies.
We are working with the Organisation for Economic Co-operation and Development (OECD) to explore the regulatory challenges of the emerging digital economy.
We will improve awareness of the effects of regulation on trade among government departments and regulators so that the impacts of regulatory divergence are systematically considered.
We will seek to include ambitious chapters on good regulatory practices and regulatory co-operation in future free trade agreements that the UK negotiates following our exit from the European Union.
We will continue working alongside other nations in the international and regional standards organisations, to help secure globally accepted standards for innovators to collaborate effectively in international markets.
We are funded solely by our most generous readers and we want to keep this way. Help SILVIEW.media deliver more, better, faster, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
One of the most maleficent characters in Trump’s menagerie is this psychopath he named as leader of Operation Warp Speed, Moncef Slaoui, former GSK and Moderna boss having a bigger body count than the Spanish Flu. Actually Kushner picked him in Trumps name, but anyway, after we wrote extensive viral exposes on his past, a team of “specialists” brushed up his online presence and then he laid low for a while. But his silence is over and his newest interviews confirm everything we’ve wrote about him and Covid-19.
For the best understanding of this article, you have to read it as a follow up to four previous pieces that are anyway essential readings:
“If you take the first Operation Warp Speed vaccine you will get an unexpected surprise: micromanaged tracking by Big Tech for up to two years, who will know more about you than you know about yourself. There is no guarantee that tracking will stop after two years.” writes Technocracy News
” It should become apparent that the military/industrial complex that is running Warp Speed is functionally merged with Big Tech like Google and Oracle. And then, there is the federal government itself that is driving the entire vaccination program”, adds TN and they’re not wrong.
Moncef Slaoui, the official head of Operation Warp Speed, told the Wall Street Journal last week that all Warp Speed vaccine recipients in the US will be monitored by “incredibly precise . . . tracking systems” for up to two years and that tech giants Google and Oracle would be involved.
Last week, a rare media interview given by the Trump administration’s “Vaccine Czar” offered a brief glimpse into the inner workings of the extremely secretive Operation Warp Speed (OWS), the Trump administration’s “public-private partnership” for delivering a Covid-19 vaccine to 300 million Americans by next January. What was revealed should deeply unsettle all Americans.
During an interview with the Wall Street Journal published last Friday, the “captain” of Operation Warp Speed, career Big Pharma executive Moncef Slaoui, confirmed that the millions of Americans who are set to receive the project’s Covid-19 vaccine will be monitored via “incredibly precise . . . tracking systems” that will “ensure that patients each get two doses of the same vaccine and to monitor them for adverse health effects.” Slaoui also noted that tech giants Google and Oracle have been contracted as part of this “tracking system” but did not specify their exact roles beyond helping to “collect and track vaccine data.”
The day before the Wall Street Journal interview was published, the New York Times published a separate interview with Slaoui where he referred to this “tracking system” as a “very active pharmacovigilance surveillance system.” During a previous interview with the journal Science in early September, Slaoui had referred to this system only as “a very active pharmacovigilance system” that would “make sure that when the vaccines are introduced that we’ll absolutely continue to assess their safety.” Slaoui has only recently tacked on the words “tracking” and “surveillance” to his description of this system during his relatively rare media interviews.
While Slaoui himself was short on specifics regarding this “pharmacovigilance surveillance system,” the few official documents from Operation Warp Speed that have been publicly released offer some details about what this system may look like and how long it is expected to “track” the vital signs and whereabouts of Americans who receive a Warp Speed vaccine.
This is basically what we meant by “It’s about data and vaccines” in our headline above. And 5G will follow Covid around because all this data needs carried by a medium and many antennas. Which, while doing their work, can also produce Covid-like symptoms, as a bonus benefit for the Covidiocracy orchestrators.
The Last American Vagabond takes it from here into finer details in one of his latest posts, demonstrating we’re guinea pigs and this is how they will study us:
Two official OWS documents released in mid-September state that vaccine recipients—expected to include a majority of the US population—would be monitored for twenty-four months after the first dose of a Covid-19 vaccine is administered and that this would be done by a “pharmacovigilance system.”
In the OWS document entitled “From the Factory to the Frontlines,” the Department of Health and Human Services (HHS) and the Department of Defense (DOD) stated that, because Warp Speed vaccine candidates use new unlicensed vaccine production methods that “have limited previous data on safety in humans . . . the long-term safety of these vaccines will be carefully assessed using pharmacovigilance surveillance and Phase 4 (post-licensure) clinical trials.”
The key objective of pharmacovigilance is to determine each vaccine’s performance in real-life scenarios, to study efficacy, and to discover any infrequent and rare side effects not identified in clinical trials. OWS will also use pharmacovigilance analytics, which serves as one of the instruments for the continuous monitoring of pharmacovigilance data. Robust analytical tools will be used to leverage large amounts of data and the benefits of using such data across the value chain, including regulatory obligations.
In addition, Moncef Slaoui and OWS’s vaccine coordinator, Matt Hepburn, formerly a program manager at the Pentagon’s controversial Defense Advanced Research Projects Agency (DARPA), had previously published an article in the New England Journal of Medicine that stated that “because some technologies have limited previous data on safety in humans, the long-term safety of these vaccines will be carefully assessed using pharmacovigilance surveillance strategies.”
The use of pharmacovigilance on those who receive the vaccine is also mentioned in the official Warp Speed “infographic,” which states that monitoring will be done in cooperation with the Food and Drug Administration (FDA) and the Centers for Disease Control and Protection (CDC) and will involve “24 month post-trial monitoring for adverse effects.”
In a separate part of that same document, OWS describes one of its “four key tenets” as “traceability,” which has three goals: to “confirm which of the approved vaccines were administered regardless of location (private/public)”; to send a “reminder to return for second dose”; and to “administer the correct second dose.”
Regarding a Covid-19 vaccine requiring more than one dose, a CDC document associated with Operation Warp Speed states:
For most Covid-19 vaccine products, two doses of vaccine, separated by 21 or 28 days, will be needed. Because different Covid-19 vaccine products will not be interchangeable, a vaccine recipient’s second dose must be from the same manufacturer as their first dose. Second-dose reminders for vaccine recipients will be critical to ensure compliance with vaccine dosing intervals and achieve optimal vaccine effectiveness.
The CDC document also references a document published in August by the Johns Hopkins Center for Health Security, associated with the Event 201 and Dark Winter simulations, as informing its Covid-19 vaccination strategy. The Johns Hopkins paper, which counts Dark Winter co-organizer Thomas Inglesby as one of its authors, argues that existing “passive reporting” systems managed by the CDC and FDA should be retooled to create “an active safety surveillance system directed by the CDC that monitors all [Covid-19] vaccine recipients—perhaps by short message service or other electronic mechanisms.”
Despite the claims in these documents that the “pharmacovigilance surveillance system” would intimately involve the FDA, top FDA officials stated in September that they were barred from attending OWS meetings and told reporters they could not explain the operation’s organization or when or with what frequency its leadership meets. The FDA officials did state, however, that they “are still allowed to interact with companies developing products for OWS,” STAT news reported.
In addition, the FDA has apparently “set up a firewall between the vast majority of staff and the initiative [Operation Warp Speed]” that appears to drastically limit the number of FDA officials with any knowledge of or involvement in Warp Speed. The FDA’s director of the Center for Drug Evaluation and Research, Janet Woodcock, is the only FDA official listed as having any direct involvement in OWS and appears to be personally managing this “firewall” at the FDA. Woodcock describes herself as a long-time advocate for the use of “big data” in the evaluation of drug and vaccine safety and has been intimately involved in FDA precursors to the coming Warp Speed “pharmacovigilance surveillance system” known as Sentinel and PRISM, both of which are discussed later in this report.
Woodcock is currently on a temporary leave of absence from her role as the director of the Center for Drug Evaluation and Research, which allows her to focus her complete attention on overseeing aspects of Operation Warp Speed on behalf of the FDA’s Office of the Commissioner. Her temporary replacement at the FDA, Patrizia Cavazzoni, is “very aligned with Janet and where the agency is going,” according to media reports. Cavazzoni is a former executive at Pfizer, one of the companies producing a vaccine for OWS. That vaccine is set to begin testing in children as young as 12 years old.
The extreme secrecy of Operation Warp Speed has affected not only the FDA but also the CDC, as a CDC expert panel normally involved in developing the government’s vaccine distribution strategies was “stonewalled” by Matt Hepburn, OWS’s vaccine coordinator, who bluntly refused to answer several of the panel’s “pointed questions” about the highly secretive operation.
More Secret Contracts
While Moncef Slaoui and Warp Speed documents provide few details regarding what this “tracking system” would entail, Slaoui did note in his recent interview with the Wall Street Journal that tech giants Google and Oracle had been contracted to “collect and track vaccine data” as part of this system. Neither Google nor Oracle, however, has announced receipt of a contract related to Operation Warp Speed, and the DOD and HHS, similarly, have yet to announce the awarding of any Warp Speed contract to either Google or Oracle. In addition, searches on the US government’s Federal Register and on the official website for federally awarded contracts came up empty for any contract awarded to Google or Oracle that would apply to any such “pharmacovigilance” system or any other aspect of Operation Warp Speed.
Given my previous reporting on the use of a nongovernment intermediary for awarding OWS contracts to vaccine companies, it seems likely that Warp Speed contracts awarded to Google and Oracle were made using a similar mechanism. In an October 6, 2020, report for The Last American Vagabond, I noted that $6 billion in Warp Speed contracts awarded to vaccine companies were made through Advanced Technology International (ATI), a government contractor that works mainly with the military and surveillance technology companies and whose parent company has strong ties to the CIA and the 2001 Dark Winter simulation. HHS, which is supposedly overseeing Operation Warp Speed, claimed to have “no record” of at least one of those contracts. Only one Warp Speed vaccine contract, which did not involve ATI and was awarded directly by HHS’s Biomedical Advanced Research and Development Authority, was recently obtained by KEI Online. Major parts of the contract, however, including the section on intellectual property rights, were redacted in their entirety.
If the Warp Speed contracts that have been awarded to Google and Oracle are anything like the Warp Speed contracts awarded to most of its participating vaccine companies, then those contracts grant those companies diminished federal oversight and exemptions from federal laws and regulations designed to protect taxpayer interests in the pursuit of the work stipulated in the contract. It also makes them essentially immune to Freedom of Information Act (FOIA) requests. Yet, in contrast to the unacknowledged Google and Oracle contracts, vaccine companies have publicly disclosed that they received OWS contracts, just not the terms or details of those contracts. This suggests that the Google and Oracle contracts are even more secretive.
A major conflict of interest worth noting is Google’s ownership of YouTube, which recently banned on its massive multimedia platform all “misinformation” related to concerns about a future Covid-19 vaccine. With Google now formally part of Operation Warp Speed, it seems likely that any concerns about OWS’s extreme secrecy and the conflicts of interest of many of its members (particularly Moncef Slaoui and Matt Hepburn) as well as any concerns about Warp Speed vaccine safety, allocation and/or distribution may be labeled “Covid-19 vaccine misinformation” and removed from YouTube.
From the NSA to the FDA: The New PRISM
Though the nature of this coming surveillance system for Covid-19 vaccine recipients has yet to be fully detailed by Warp Speed or the tech companies the operation has contracted, OWS documents and existing infrastructure at the FDA offer a clue as to what this system could entail.
For instance, the Warp Speed document “From the Factory to the Frontlines” notes that the pharmacovigilance system will be a new system created exclusively for OWS that will be “buil[t] off of existing IT [information technology] infrastructure” and will fill any “gaps with new IT solutions.” It then notes that “the Covid-19 vaccination program requires significant enhancement of the IT that will support enhancements and data exchange that are critical for a multi-dose candidate to ensure proper administration of a potential second dose.” The document also states that all data related to the OWS vaccine distribution effort “will be reported into a common IT infrastructure that will support analysis and reporting,” adding that this “IT infrastructure will support partners with a broad range of tools for record-keeping, data on who is being vaccinated, and reminders for second doses.”
Though some Warp Speed documents hint as to the existing IT systems that will serve as the foundation for this new tracking system, arguably the most likely candidate is the FDA-managed Sentinel Initiative, which was established in 2009 during the H1N1 Swine flu pandemic. Like Operation Warp Speed itself, Sentinel is a public-private partnership and involves the FDA, private business, and academia.
According to its website, Sentinel’s “main goal is to improve how FDA evaluates the safety and performance of medical products” through big data, with an additional focus on “learning more about potential side effects.” Media reports describe Sentinel as “an electronic surveillance system that aggregates data from electronic medical records, claims and registries that voluntarily participate and allows the agency to track the safety of marketed drugs, biologics and medical devices.”
One of Sentinel’s main proponent at the FDA is Janet Woodcock, who has aggressively worked to expand the program as director of the FDA’s Center for Drug Evaluation and Research, with a focus on Sentinel’s use in “post-market effectiveness studies.” As previously mentioned, Woodcock is the only FDA official listed among the ninety or so “leaders” of OWS, most of whom are part of the US military and lack any health-care or vaccine-production experience.
Woodcock’s temporary replacement at the FDA, Patrizia Cavazzoni, is also very active in efforts to expand Sentinel. STAT news reported earlier this year that Cavazzoni previously “served on the sterling committee of I-MEDS, an FDA-industry partnership which allows drug makers to pay for use of the FDA’s real-world data system known as Sentinel to complete certain safety studies more quickly.”
Sentinel has a series of “collaborating partners” that “provide healthcare data and scientific, technical, and organizational expertise” to the initiative. These collaborating partners include intelligence contractor Booz Allen Hamilton, tech giant IBM, and major US health insurance companies such as Aetna and Blue Cross Blue Shield, among many others. In addition, Sentinel’s Innovation Center, which it describes as the program’s “test bed to identify, develop, and evaluate innovative methods,” is partnered with Amazon, General Dynamics, and Microsoft. Sentinel also has a Community Building and Outreach Center, which is managed by Deloitte consulting, one of the largest consultancy firms in the world that is known for seeking to fill its ranks with former CIA officials.
The Sentinel system’s specific surveillance program aimed at monitoring vaccine effectiveness is known as the Post-licensure Rapid Immunization Safety Monitoring Program, better known as PRISM. Sentinel’s PRISM was “developed to monitor vaccine safety, but [to date] has never been used to assess vaccine effectiveness.” PRISM was initially launched alongside the Sentinel Initiative itself in 2009 “in response to the need to monitor the safety of the H1N1 influenza vaccine” after it was licensed, marketed, and administered. Yet, as previously mentioned, PRISM has yet to be used to assess the effectiveness of any vaccine while quietly expanding for nearly a decade, which implies that the stakeholders in the Sentinel Initiative have a plan to implement this “safety surveillance system” at some point.
The name PRISM may remind readers of the National Security Agency (NSA) program of the same name that became well known throughout the United States following the Edward Snowden revelations. Given this association, it is worth noting that the NSA, as well as the Department of Homeland Security (DHS), are now officially part of Operation Warp Speed and appear to be playing a role in the development of Warp Speed’s “pharmacovigilance surveillance system.” The addition of the NSA and the DHS to the initiative, of course, greatly increases the involvement of US intelligence agencies in the operation, which itself is “dominated” by the military and sorely lacking in civilian public health officials.
CyberScoop first reported in early September that members of the NSA’s Cybersecurity Directorate were involved in Operation Warp Speed, with their role—as well as that of DHS—being framed mainly as offering “cybersecurity advice” to the initiative. However, the NSA and DHS are also offering “guidance” and “services” to both the other federal agencies involved in Warp Speed as well as OWS contractors, which now include Google and Oracle.
Companies collecting data for pubs and restaurants to help them fulfil their contact-tracing duties are harvesting confidential customer information to sell.
Legal experts have warned of a “privacy crisis” caused by a rise in companies exploiting QR barcodes to take names, addresses, telephone numbers and email details, before passing them on to marketers, credit companies and insurance brokers.
The “quick response” mobile codes have been widely adopted by the hospitality, leisure and beauty industries as an alternative to pen-and-paper visitor logs since the government ordered businesses to collect contact details to give to NHS Test and Trace if required.
Any data collected should be kept by the business for 21 days and must not be used “for any purposes other than for NHS Test and Trace”, according to government guidelines.
Gaurav Malhotra, director of Level 5, a software development company that supplies the government, said data could end up in the hands of scammers. “If you’re suddenly getting loads of texts, your data has probably been sold on from track-and-trace systems,” he said.
One of the firms claiming to offer a privacy-compliant QR code service is Pub Track and Trace (PUBTT), an organisation based in Huddersfield charging pubs £20 a month to keep track of visitors, who are asked to provide their name, phone number and email address.
It may also “collect, use, store and transfer” records of access to certain premises including “time, ID number and CCTV images”.
Ordamo, which provides track and trace services for restaurants, states that data from website visitors is “retained for 25 years”, a duration Hazel Grant, head of privacy at Fieldfisher, a law firm, said would be “very difficult to justify”. Ordamo did not respond to requests for comment.
The Information Commissioner’s Office is assessing 15 companies that “provide services to venues to collect customer logs”.
We are funded solely by our most generous readers and we want to keep this way. Help SILVIEW.media deliver more, better, faster, please donate here, anything helps. Thank you!
! Articles can always be subject of later editing as a way of perfecting them
I still haven’t seen any evidence of a novel coronavirus being properly isolated in a lab as per Koch’s Postulate, and that’s the only official scientific homologation of a virus. But “follow the science” is what the cry, so here’s the latest in 5G science, from US’ NIH website and PubMed.
5G Technology and induction of coronavirus in skin cells
In this research, we show that 5G millimeter waves could be absorbed by dermatologic cells acting like antennas, transferred to other cells and play the main role in producing Coronaviruses in biological cells. DNA is built from charged electrons and atoms and has an inductor-like structure. This structure could be divided into linear, toroid and round inductors. Inductors interact with external electromagnetic waves, move and produce some extra waves within the cells. The shapes of these waves are similar to shapes of hexagonal and pentagonal bases of their DNA source. These waves produce some holes in liquids within the nucleus. To fill these holes, some extra hexagonal and pentagonal bases are produced. These bases could join to each other and form virus-like structures such as Coronavirus. To produce these viruses within a cell, it is necessary that the wavelength of external waves be shorter than the size of the cell. Thus 5G millimeter waves could be good candidates for applying in constructing virus-like structures such as Coronaviruses (COVID-19) within cells.
1Instytut Medycyny Pracy im. prof. J. Nofera / Nofer Institute of Occupational Medicine, Łódź, Poland (Zakład Ochrony Radiologicznej / Department of Radiological Protection).
2Politechnika Wrocławska / Wrocław University of Sciences and Technology, Wrocław, Poland (Katedra Telekomunikacji i Teleinformatyki / Department of Telecommunications and Teleinformatics).
3Instytut Medycyny Pracy im. prof. J. Nofera / Nofer Institute of Occupational Medicine, Łódź, Poland (Zakład Fizjologii Pracy i Ergonomii / Department of Work Physiology and Ergonomics).
4Centralny Instytut Ochrony Pracy – Państwowy Instytut Badawczy / Central Institute for Labor Protection – National Research Institute, Warsaw, Poland (Zakład Bioelektromagnetyzmu / Department of Bioelectromagnetism).
5Wojskowy Instytut Higieny i Epidemiologii / Military Institute of Hygiene and Epidemiology, Warsaw, Poland.
6Instytut Medycyny Pracy im. prof. J. Nofera / Nofer Institute of Occupational Medicine, Łódź, Poland.
There is an ongoing discussion about electromagnetic hazards in the context of the new wireless communication technology – the fifth generation (5G) standard. Concerns about safety and health hazards resulting from the influence of the electromagnetic field (EMF) emitted by the designed 5G antennas have been raised. In Poland, the level of the population’s exposure to EMF is limited to 7 V/m for frequencies above 300 MHz. This limitation results from taking into account the protective measures related not only to direct thermal hazards, but also to diversified indirect and long-term threats. Many countries have not established legal requirements in this frequency range, or they have introduced regulations based on recommendations regarding protection against direct thermal risks only (Council Recommendation 1999/519/EC). For such protection, the permissible levels of electric field intensity are 20-60 V/m (depending on the frequency). This work has been created through an interdisciplinary collaboration of engineers, biologists and doctors, who have been for many years professionally dealing with the protection of the biosphere against the negative effects of EMF. It presents the state of knowledge on the biological and health effects of the EMF emitted by mobile phone devices (including millimeter waves which are planned to be used in the 5G network). A comparison of the EU recommendations and the provisions on public protection being in force in Poland was made against this background. The results of research conducted to date on the biological effects of the EMF radiofrequency emitted by mobile telecommunication devices, operating with the frequencies up to 6 GHz, do not allow drawing any firm conclusions; however, the research evidence is strong enough for the World Health Organization to classify EMF as an environmental factor potentially carcinogenic to humans. At the moment, there is a shortage of adequate scientific data to assess the health effects of exposure to electromagnetic millimeter waves, which are planned to be used in the designed 5G devices. Nevertheless, due to the fact that there are data indicating the existence of biophysical mechanisms of the EMF influence that may lead to adverse health effects, it seems necessary to use the precautionary principle and the ALARA principle when creating environmental requirements for the construction and exploitation of the infrastructure of the planned 5G system. Med Pr. 2020;71(1):105-13.
Before we enter the official documents, please do the following experiment: Pick any number between 10 and 1000. Write it in an online search engine, followed by “new cases”. Watch hundreds and thousands of news pieces reporting that specific number of cases in hundreds different locations, especially US. Remember that 46% of the officially reported Covid-19 fatalities in US come from New York. Compare that with the distribution in the news. If you have basic knowledge of calculus, ask yourself: How many billions people have been reported in total? What volume of work was required for all that reporting, in a time when much of the media was laid off or working from home, while the volume of events/news was never higher?
China, the first epicentre of this disease and renowned for its technological advance in this field, has tried to use this to its real advantage. Its uses seem to have included support for measures restricting the movement of populations, forecasting the evolution of disease outbreaks and research for the development of a vaccine or treatment. With regard to the latter aspect, AI has been used to speed up genome sequencing, make faster diagnoses, carry out scanner analyses or, more occasionally, handle maintenance and delivery robots (A. Chun, In a time of coronavirus, China’s investment in AI is paying off in a big way, South China Morning post, 18 March 2020).
Its contributions, which are also undeniable in terms of organising better access to scientific publications or supporting research, does not eliminate the need for clinical test phases nor does it replace human expertise entirely. The structural issues encountered by health infrastructures in this crisis situation are not due to technological solutions but to the organisation of health services, which should be able to prevent such situations occurring (Article 11 of the European Social Charter). Emergency measures using technological solutions, including AI, should also be assessed at the end of the crisis. Those that infringe on individual freedoms should not be trivialised on the pretext of a better protection of the population. The provisions of Convention 108+ should in particular continue to be applied.
The contribution of artificial intelligence to the search for a cure
The first application of AI expected in the face of a health crisis is certainly the assistance to researchers to find a vaccine able to protect caregivers and contain the pandemic. Biomedicine and research rely on a large number of techniques, among which the various applications of computer science and statistics have already been making a contribution for a long time. The use of AI is therefore part of this continuity.
The predictions of the virus structure generated by AI have already saved scientists months of experimentation. AI seems to have provided significant support in this sense, even if it is limited due to so-called “continuous” rules and infinite combinatorics for the study of protein folding. The American start-up Moderna has distinguished itself by its mastery of a biotechnology based on messenger ribonucleic acid (mRNA) for which the study of protein folding is essential. It has managed to significantly reduce the time required to develop a prototype vaccine testable on humans thanks to the support of bioinformatics, of which AI is an integral part.
Indeed, in the weeks following the appearance of the new coronavirus in Wuhan, China, in December 2019, nearly 2,000 research papers were published on the effects of this new virus, on possible treatments, and on the dynamics of the pandemic. This influx of scientific literature naturally reflects the eagerness of researchers to deal with this major health crisis, but it also represents a real challenge for anyone hoping to exploit it.
Microsoft Research, the National Library of Medicine and the Allen Institute for AI (AI2) therefore presented their work on 16 March 2020, which consisted of collecting and preparing more than 29,000 documents relating to the new virus and the broader family of coronaviruses, 13,000 of which were processed so that computers could read the underlying data, as well as information on authors and their affiliations. Kaggle, a Google subsidiary and platform that usually organisesdata science competitions, created challenges around 10 key questions related to the coronavirus. These questions range from risk factors and non-drug treatments to the genetic properties of the virus and vaccine development efforts. The project also involves the Chan Zuckerberg Initiative (named after Facebook founder Mark Zuckerberg and his wife Priscilla Chan) and Georgetown University’s Center for Security and Emerging Technologies (W. Knight, Researchers Will Deploy AI to Better Understand Coronavirus, Wired, March 17, 2020).
Artificial intelligence, observer and predictor of the evolution of the pandemic
The International Research Centre for Artificial Intelligence (IRCAI) in Slovenia, under the auspices of UNESCO, has launched an “intelligent” media watch on coronavirus called Corona Virus Media Watch which provides updates on global and national news based on a selection of media with open online information. The tool, also developed with the support of the OECD and the Event Registry information extraction technology, is presented as a useful source of information for policy makers, the media and the public to observe emerging trends related to Covid-19 in their countries and around the world.
Artificial intelligence to assist healthcare personnel
For their part, two Chinese companies have developed AI-based coronavirus diagnostic software. The Beijing-based start-up Infervision has trained its software to detect lung problems using computed tomography (CT) scans. Originally used to diagnose lung cancer, the software can also detect pneumonia associated with respiratory diseases such as coronavirus. At least 34 Chinese hospitals are reported to have used this technology to help them screen 32,000 suspected cases (T. Simonite, Chinese Hospitals Deploy AI to Help Diagnose Covid-19, Wired, February 26, 2020).
The Alibaba DAMO Academy, the research arm of the Chinese company Alibaba, has also trained an AI system to recognise coronaviruses with an accuracy claimed to be 96%. According to the company, the system could process the 300 to 400 scans needed to diagnose a coronavirus in 20 to 30 seconds, whereas the same operation would usually take an experienced doctor 10 to 15 minutes. The system is said to have helped at least 26 Chinese hospitals to review more than 30,000 cases (C. Li, How DAMO Academy’s AI System Detects Coronavirus Cases, Alizila, March 10, 2020).
In South Korea, AI is reported to have helped reduce the time needed to design testing kits based on the genetic make-up of the virus to a few weeks, when it would normally take two to three months. The biotech company Seegene used its automated test development system to develop the test kit and distribute it widely. Large-scale testing is indeed crucial to overcome containment measures and this testing policy seems to have contributed to the relative control of the pandemic in this country, which has equipped 118 medical establishments with this device and tested more than 230,000 people (I. Watson, S. Jeong, J. Hollingsworth, T. Booth, How this South Korean company created coronavirus test kits in three weeks, CNN World, March 13, 2020).
Artificial intelligence as a tool for population control
Finally, attempts at misinformation have proliferated on social networks and the Internet. Whether it concerns the virus itself, the way it spreads or the means to fight its effects, many rumours have circulated (“Fake news” and disinformation about the SARS-CoV2 coronavirus, INSERM, 19 February 2020). AI is a technology already used with some effectiveness by platforms to fight against inappropriate content. UNICEF adopted a statement on 9 March 2020 on misinformation about the coronavirus in which it intends to “actively take steps to provide accurate information about the virus by working with the World Health Organization, government authorities and online partners such as Facebook, Instagram, LinkedIn and TikTok, to ensure that accurate information and advice is available, as well as by taking steps to inform the public when inaccurate information appears”. The enactment of restrictive measures in Council of Europe member States to avoid fuelling public concern is also envisaged. However, the Council of Europe Committee of Experts on the Media Environment and Media Reform (MSI-REF) underlined in a statement of 21 March 2020 that “the crisis situation should not be used as a pretext to restrict public access to information. Nor should States introduce restrictions on media freedom beyond the limits allowed by Article 10 of the European Convention on Human Rights”. The Committee also highlights that “member States, together with all media actors, should strive to ensure an environment conducive to quality journalism”.
Artificial intelligence: an evaluation of its use in the aftermath of a crisis
Digital technology, including information technology and AI, are therefore proving to be important tools to help build a coordinated response to this pandemic. The multiple uses also illustrate the limits of what can currently be achieved by this very technology, which we cannot expect to compensate for structural difficulties such as those experienced by many health care institutions around the world. The search for efficiency and cost reduction in hospitals, often supported by information technology, should not reduce the quality of services or compromise universal access to care, even in exceptional circumstances.
It should be recalled that Article 11 of the European Social Charter (ratified by 34 of the 47 member States of the Council of Europe) establishes a right to health protection which commits the signatories “to take, either directly or in co-operation with public and private organisations, appropriate measures designed in particular to : 1°) to eliminate, as far as possible, the causes of ill-health; 2°) to provide consultation and education services for the improvement of health and the development of a sense of individual responsibility for health; 3°) to prevent, as far as possible, epidemic, endemic and other diseases, as well as accidents.”
Executives from Amazon, Google, Microsoft, Apple and Facebook met officials at Downing Street on Wednesday to discuss their role in the coronavirus crisis. One of the things discussed was their role in “modelling and tracking data”. In similar meetings at the White House, meanwhile, companies were asked how they could use artificial intelligence. A World Health Organization report last month said AI and big data were a key part of China’s response to the virus.
I’m reporting from captivity in Agadir, a Moroccan city which I’ve just found out it’s the birth-place of Moncef Slaoui, the newly appointed head of “Operation Warp Speed” , Trump’s mass-vaccination campaign. And the that’s the least disturbing thing I have to tell you. I probably need protection now, I’m warned, authorities here are not big fans of free speech, people have been arrested for much less. But this isn’t much of a life anyway; all worth it if you spread this knowledge like fire. May the public eye be my protection, if any.
US President Donald Trump selected Moroccan immunology expert Moncef Slaoui to be the head of his administration’s COVID-19 vaccine development team, working on “Operation Warp Speed.”
The Moroccan expert, 60, will serve as the US government’s “therapeutics czar” to help coordinate the development of vaccines and treatments. The role is shared between the US Department of Health and Human Services and the Department of Defense.
Slaoui will be assisted by Army Gen. Gustave Perna, the commander of United States Army Materiel Command.
Slaoui earned a Ph.D. in molecular biology and immunology from the Free University of Brussels, Belgium, and completed his postdoctoral studies at Harvard Medical School and Tufts University School of Medicine, Boston.
He was the former head of the vaccines division at GlaxoSmithKline (GSK), where he oversaw the development of various vaccines: Rotarix, Synflorix, and Cervarix. In 2007, he announced plans to establish a neurosciences research group in Shanghai that would employ a thousand scientists and cost $100 million; it failed miserably and ceased operations in August 2017.
In 2008, Slaoui led the $720 million acquisition of Sirtris Pharmaceuticals, which folded in 2013. In 2012, he oversaw GSK’s purchase of Human Genome Sciences for over $3 billion. In 2015 he won European approval for the world’s first malaria vaccine (Mosquirix).
When he retired from the drugmaker in 2017, GSK was still working on the vaccine for Ebola.
GSK is now working on a COVID-19 vaccine with Sanofi, the French multinational pharma giant.
“Not long after leaving GSK, the enthusiastic and outgoing Slaoui started joining biotech boards, with welcomes at SutroVax, mRNA player Moderna as well as the public outfit Intellia $NTLA, one of a handful of CRISPR/Ca9 gene editing startups dominating the field. Then, a little over a month ago, he dropped off the Intellia crew, citing a conflict but not explaining it.” – Endpoints
But his biggest business move was becoming a partner at Medicxi Capital, a biotechnology venture capital firm in the Philadelphia, Pennsylvania area.
Medicxi has built a highly experienced team and, through the scientific advisory boards (SABs) of each of its funds, has access to some of the most respected names in the pharma industry. As well as Medicxi’s senior team, now including Dr Slaoui, external members and observers on the SABs to Medicxi’s funds included (2017):
Dr Vasant (Vas) Narasimhan, Global Head of Drug Development, Chief Medical Officer and Chief Executive Officer Elect
Dr Evan Beckman, Global Head of Translational Medicine at NIBR
Nigel Sheail, Head of Business Development and Licensing
From Verily Life Sciences:
Dr Andy Conrad, Chief Executive Officer
Dr Robert Califf, Advisor and former US FDA Commissioner
Dr Patrick Vallance President, R&D
Dr Paul-Peter Tak Senior Vice President R&D Pipeline, Global Development Leader and Chief Immunology Officer
From Johnson & Johnson:
Dr. Paul Stoffels, Executive Vice President, Chief Scientific Officer
Dr. Bill Hait, Global Head, Janssen Research & Development
Dr Patrick Verheyen Global Head, Janssen Business Development
Michèle Ollier, co-founder and Partner at Medicxi, said: “Moncef has made a tremendous contribution through his role on our SABs and we look forward to his continued energetic and insightful contribution as a Partner at Medicxi. Our SAB meetings are challenging, insightful and inspiring, and contribute hugely to how we steer and advise our portfolio companies.”
Medicxi is based in London, Geneva and Jersey. The Company’s mission is to invest across the full healthcare continuum. Medicxi was established by the former Index Ventures life sciences team. Medicxi manages the legacy life science portfolio of Index Ventures as well as the new funds launched as Medicxi, Medicxi Ventures 1 (MV1) and Medicxi Growth 1 (MG1) focusing on early-stage and late-stage investments in life sciences.
GSK, Johnson & Johnson and Novartis, three of the world’s largest pharmaceutical companies back Medicxi along with Verily, an Alphabet company. These companies, whilst participating in the SABs of the funds, do not receive any preferential rights to the portfolio companies.
Medicxi’s team has been investing in life sciences for over 20 years and has backed many successful companies, including Genmab (NASDAQ Copenhagen: GEN), PanGenetics (sold to AbbVie), Molecular Partners (SWX: MOLN), XO1 (sold to Janssen) Egalet (NASDAQ: EGLT), Minerva Neurosciences (NASDAQ: NERV) and Versartis (NASDAQ: VSAR).
Since 2017, Slaoui has been also sitting on the board of Moderna, a biotechnology company also pursuing a COVID-19 vaccine, based in Cambridge, Massachusetts.
The other problem, because they always come in pairs: Trump awarded Moderna almost $0.5Billion from public money a few days before nominating Slaoui. CNN reported on May 18th:
“Valera’s efforts (Moderna subsidiary) have resulted in the demonstration of preclinical efficacy of Moderna’s mRNA-based vaccines in multiple viral disease models, Moderna said.
In the partnership with the Gates Foundation, Valera will apply its mRNA vaccine platform as well as Moderna’s drug platform Messenger RNA Therapeutics™. Designed to produces human proteins, antibodies, and entirely novel protein constructs inside patient cells, the therapeutics are secreted or active intracellularly.” – Genetic Engineering & Biotechnology News
What, you think that’s bad? What if I told you this is the last one in a very long series of collaborations between the two?
Why is no one talking about this chapter of Moncef Slaoui’s career? Well, I am:
I find most relevant this transhumanist project Slaoui worked on with Google from 2016, as reported by Bloomberg:
<<The recent partnership between GlaxoSmithKline (GSK) and Alphabet (Google) further opens the door for development in the biotechnology industry’s experimental “bioelectronics” segment. Chairman of Vaccines at GlaxoSmithKline Dr. Moncef Slaoui thinks the partnership could create an entirely new industry. “I think this is a whole new industry as big as the pharmaceutical industry … there’s a whole new world that we’re opening here which is dealing with electrical signals to connect with our biology and changes functioning,” Slaoui told CNBC’s Meg Tirrell on “Squawk Box” Monday morning. Calling Alphabet’s Verily Life Services a “really exciting partner,” Slaoui says GlaxoSmithKline shares “a very common vision of integrating electronics and big data analytics and technologies with medicines and biology.” “They bring to us the engineering capabilities, the electronics, the low power technologies and the wireless technologies that are critical to miniaturize these devices, power them and extract information from them,” Slaoui noted.>>
“GSK has been interested in this field for years, and in 2013 announced a $1 million prize for innovative bioelectronics research. In a press statement, GSK’s Moncef Slaoui said: “Many of the processes of the human body are controlled by electrical signals firing between the nervous system and the body’s organs, which may become distorted in many chronic diseases.” He said bioelectronic seeks to “correct the irregular [electrical] patterns found in disease states, using miniaturized devices attached to individual nerves.” – The Verge
And having in mind the technological terror, the transhumanist/eugenicist obsessions brought by the coronavirus policy-makers today, one quote from the same source above hits home. This whole business falls right in the arms of anyone associating the coronavirus pandemic with human microchipping. Slaoui cited animal models as the indicator that bioelectronics can treat chronic diseases with a number of different devices.
The devices themselves are very small, about “the size of a rice grain”, and can “either stimulate or black the electric signals that our brains sense through our nerves to control the functioning of our organs… The limitations are around power as power requires energy and energy means heat and heat doesn’t go well with biology.
It gets weirder
Slaoui rejected reports in late March of his involvement with a US government task force for COVID-19 vaccine development and denied as recently as May 11 any intention to work with the Trump administration. WHY?? Morocco World News reported in March 31st: “The doctor said he has no working arrangements with the US government in a statement to Moroccan French-language newspaper L’Economiste. Several local news outlets claimed that the former chairman of pharmaceutical giant GlaxoSmithKline (GSK) is part of a task force that is researching a vaccine to clamp down on the spread of the virus. The international expert is currently a member of the board of directors of American biotechnology company Moderna. Slaoui explained that he is part of the company’s research and development committee. The committee has received support from federal organizations to help fund the development of a COVID-19 vaccine. “
White House senior adviser Jared Kushner, the son-in-law of President Trump, was among the officials who interviewed Slaoui for the role.
Jared Kushner went there. Jared Kushner personally picked America’s new “Vaccine Czar” Moncef Slaoui precisely one year after the meeting. Jared Kushner is a Zionist. Jared Kushner is Trump’s son law.
To avoid a conflict of interest, Slaoui resigned from the board of the Massachusetts-based biotech firm Moderna, which had been developing a vaccine for the coronavirus. He stepped down but he didn’t give up his stakes in Moderna, as the Daily Beast reports:
“Slaoui’s ownership of 156,000 Moderna stock options, disclosed in required federal financial filings, sparked concerns about a conflict of interest. Democratic Massachusetts Senator Elizabeth Warren called Slaoui out over the matter on Twitter: “It is a huge conflict of interest for the White House’s new vaccine czar to own $10 million of stock in a company receiving government funding to develop a COVID-19 vaccine. Dr. Slaoui should divest immediately.” The company’s shares skyrocketed last month after news broke of the $483 million in federal funding to work on a coronavirus vaccine. Slaoui could not immediately be reached for comment on the matter.”
Slaoui also sits on the boards of SutroVax, the Biotechnology Innovation Organization, the International AIDS Vaccine Initiative, and the PhRMA Foundation
The Moroccan expert’s main contenders for the position of chief advisor at “Operation Warp Speed” were Algeria’s Elias Zerhouni and US’ Arthur Levinson.
Zerhouni, born in 1951, is an Algerian scientist, radiologist, and biomedical engineer. The expert has held several important positions in a number of institutions, ranging from medical schools to pharmaceutical companies and government task forces.
In 2009, under the Obama administration, Zerhouni served as the first science envoy in the US and worked towards fostering scientific and technological collaboration with other countries.
Between 2011 and 2018, as a final stage in his career, Zerhouni was the President for Global Research and Development at, well, Sanofi.
The third main candidate in the race for Trump’s COVID-19 operation, Arthur Levinson, is an American businessman specialized in biotechnology.
Levinson has served as senior advisor for several companies and institutions, including Swiss healthcare multinational Hoffmann-La Roche, Amyris Biotechnologies, the Memorial Sloan Kettering Cancer Center, the California Institute for Quantitative Biosciences, and Princeton University.
The American businessman is currently the chairman of tech giant Apple and CEO of biotechnology company Calico.
“We will get to [vaccines] eventually, but we’re not there yet. If we want to lift the lockdowns, we need to fully respect them first”
Outlook on the pandemic
During an interview on April 12, Slaoui said he expects life to begin its return to normal at the beginning of 2021 after global leaders rein in the pandemic, adding that he considers his prediction “optimistic.”
He is confident “that due to the high number of COVID-19 cases, clinical studies will reach results quickly.” He believes that “by the end of May or by early June, we will know if some of these drugs work.”
“I am very optimistic that we’ll have several vaccines for COVID-19. However, the problem is not having a vaccine. The problem is producing enough to protect eight billion people,” he continued.
Which is weird, because US Government has just announced same day spending $138mil. to turbo-boost vaccine production, and I’ve published a massive investigation piece on that.
In another interview with Moroccan television channel 2M on April 13, Slaoui forecast that the COVID-19 pandemic will heavily scar the global population.
“I believe that by 2021 our reality will not be completely back to normal but it will be improved,” he argued.
Moncef Slaoui said if the virus continues to spread, there will be no way to control it other than to create a vaccine and administer it on a massive scale.
“We will get to [vaccines] eventually, but we’re not there yet. If we want to lift the lockdowns, we need to fully respect them first,” he explained.
He said countries can phase out lockdowns when there is a proven COVID-19 treatment.
Slaoui acknowledged that there are now hundreds of clinical studies underway in many countries.
He expressed optimism that due to the increasing number of COVID-19 cases, clinical studies will achieve preliminary results quickly. “I believe that by the end of May or by early June, we will know if some of these drugs work.”
Government watchdog Public Citizen on Thursday “condemned the Trump administration’s reported appointment of a former pharmaceutical executive to the White House’s task force aimed at swiftly developing a Covid-19 vaccine as another example of the White House putting management of the pandemic in the hands of private industry. “
“If the Trump administration approaches vaccine development as it has Covid-19 prevention, testing, and treatment, the world may be in for years of more extraordinary pain,” Maybarduk added. “The dangers of global vaccine rationing are profound. No one corporation has the capacity to deliver a vaccine to all the world’s people.”
In March, Trump’s FDA came under fire for awarding monopoly status to Gilead Sciences for Remdesivir, a drug it was developing for Covid-19 treatment. The company backed off its claim after a pressure campaign led by Public Citizen.
“The U.S. government must commit to sharing clinical trial data, patents, and know-how among manufacturers and with the world, to quickly achieve the mountainous scale of production that humanity needs,” the group said.
Yes, from many reputable sources it comes out that 5G radiation can cause symptoms very similar to Covid-19’s, as many other things do. But that’s not the actual connection between 5G and Covid-19. They often appear to go hand in hand because it’s all about DATA.
From U.S. Department of Defense, Washington
Statement attributed to Lt. Col. Mike Andrews, Department of Defense spokesman: “Today (May 12th 2020) the Department of Defense and the U.S. Department of Health and Human Services, announce a $138 million contract with ApiJect Systems America for “Project Jumpstart” and “RAPID USA,” which together will dramatically expand U.S. production capability for domestically manufactured, medical-grade injection devices starting by October 2020.
Spearheaded by the DOD’s Joint Acquisition Task Force (JATF), in coordination with the HHS Office of the Assistant Secretary for Preparedness and Response, the contract will support “Jumpstart” to create a U.S.-based, high-speed supply chain for prefilled syringes beginning later this year by using well-established Blow-Fill-Seal (BFS) aseptic plastics manufacturing technology, suitable for combatting COVID-19 when a safe and proven vaccine becomes available.“
This was followed immediately by President Trump announcing he will mobilize military to distribute vaccines, when available.
ApiJect is a founding member of the Rapid Consortium. A YouTube video produced by the organization states, “These facilities will make enough prefilled syringes to inject every man, woman, and child in America with just the right dose 30 days after a vaccine becomes available. Plus every prefilled syringe can have an RFID chip attached. This will allow healthcare workers to use their mobile phones to automatically capture where and when every injection takes place, helping public health officials make more informed decisions.”
“Whether health officials are running a scheduled vaccination program or an urgent pandemic response campaign, they can make better decisions if they know when and where each injection occurs. With an optional RFID/NFC tag on each BFS prefilled syringe, ApiJect will make this possible. Before giving an injection, the healthcare worker will be able to launch a free mobile app and “tap” the prefilled syringe on their phone, capturing the NFC tag’s unique serial number, GPS location and date/time. The app then uploads the data to a government-selected cloud database. Aggregated injection data provides health administrators an evolving real-time “injection map.”
Now back to the Department of Defense statement:
“By immediately upgrading a sufficient number of existing domestic BFS facilities with installations of filling-line and technical improvements, “Jumpstart” will enable the manufacture of more than 100 million prefilled syringes for distribution across the United States by year-end 2020.
The contract also enables ApiJect Systems America to accelerate the launch of RAPID USA manufactured in new and permanent U.S.-based BFS facilities with the ultimate production goal of over 500 million prefilled syringes (doses) in 2021. This effort will be executed initially in Connecticut, South Carolina and Illinois, with potential expansion to other U.S.-based locations. RAPID will provide increased lifesaving capability against future national health emergencies that require population-scale vaccine administration on an urgent basis.
RAPID’s permanent fill-finish production capability will help significantly decrease the United States’ dependence on offshore supply chains and its reliance on older technologies with much longer production lead times. These supplies can be used if a successful SARS-COV-2 vaccine is oral or intranasal rather than injectable.”
ApiJect Systems America, Inc., a public benefit corporation based here, today announced that it has been awarded an HHS-DOD Title 3, DPA contract valued up to $138 million to accelerate the building of a new U.S.-based, high-speed, population-scale emergency drug injection capability with prefilled syringes from its subsidiary RAPID USA Inc. RAPID USA’s emergency program, “Project Jumpstart” is being initiated to supply 100 million prefilled syringes by year-end.
RAPID USA’s Project Jumpstart will immediately contract with a sufficient number of existing U.S.- based Blow-Fill-Seal (BFS) facilities to install filling lines and technical upgrades to enable production of prefilled syringes before year-end. BFS is a well-established high-speed medical- grade plastics aseptic manufacturing process that specializes in the high-volume production of pharmaceutical products. Jumpstart will also purchase and stockpile 100 million Needle Hubs for ApiJect prefilled syringes. Jumpstart will develop the capability to manufacture a minimum of 30 million prefilled syringes per month once therapeutic drugs and vaccines become available.
In parallel with Project Jumpstart, RAPID USA will build a network of 30 U.S.-based BFS manufacturing lines at three different, geographically dispersed, sites. Once operational, these 30 lines will fill, finish, and package up to 330 million prefilled BFS syringes per month. Initial production will begin in late 2021. RAPID USA will also build a U.S.-based training and prototyping facility capable of supporting 500 U.S.-based jobs at RAPID USA’s three manufacturing sites.
ApiJect Systems America CEO Jay Walker commented: “ApiJect’s Title 3, DPA funding gives our subsidiary RAPID USA the capability to swiftly create the domestic surge capacity in prefilled syringes that will be needed as therapeutics and vaccines become available. Project Jumpstart is the first stage in RAPID’s HHS-DOD supported two-stage effort. Within six months, Project Jumpstart will create a surge capacity to supply 100 million prefilled syringes and more than 500 million in 2021. Stage two, running in parallel with Jumpstart, will have RAPID USA building a network of 30 U.S.-based BFS manufacturing lines, enabling a monthly production of up to 330 million BFS prefilled syringes.”
Walker continued: “When discussions with HHS ASPR first began last year ApiJect was then focused on global health, specifically injection safety in low and middle-income countries where needle reuse and contaminated multi-dose vials kill as many as two million people every year and infect 10 million or more with transmissible diseases such as HIV and Hep-C. ASPR’s leadership wanted us to turn our attention to building a U.S.-based population-scale surge capacity for flexible biodefense purposes. We started immediately, and when COVID-19 emerged as a pandemic threat, our public-private partnership with HHS, which had been created in January, accelerated to focus on building both an emergency capability as well as longer-term sustainable injection surge capacity.”
Walker further commented: “RAPID USA is led by our multi-disciplinary team of experienced engineers, pharmaceutical technology experts, and management leadership. Our team is expending extraordinary efforts to ensure that when drugs are developed and tested all Americans can receive critical injections. We will have done our part by providing the manufacturing capacity to support the necessary volume of ready-to-use prefilled syringes that contain essential medicines, be they therapeutics or vaccines. Our public-private partnership, supported by Jefferies Financial Group, and the HHS-DOD Title 3 contract, demonstrates the vital role that RAPID will play in the war against COVID-19, as well as future national health emergencies.”
Rich Handler, CEO and Brian Friedman, President of Jefferies Financial Group, Inc., commented: “Finding a solution to the COVID-19 crisis demands the best from each of us, as companies and as individual citizens. When we learned what ApiJect was doing with the U.S. Government, Health and Human Services and the Department of Defense, we saw a role where Jefferies and our nearly 4,000 global professionals could make a difference. We invested in RAPID USA as we believe it is the right step at the right time, and we will continue to support ApiJect to assure RAPID USA can do their important job of building the surge capacity needed here on U.S. soil to help put this crisis behind us.”
#FlattenTheLies Face Mask by Silview MASKS ARE BAD FOR YOU, USE THEM ONLY IF YOU HAVE NO BETTER ALTERNATIVE! OR AT PROTESTS. AND IF YOU DO, USE ONE THAT SENDS OUT THE RIGHT MESSAGE.
ABOUT APIJECT AND RAPID USA
ApiJect Systems America, Inc., is a public benefit corporation dedicated to making injectable medicines safe and available for everyone. By building a network using high-speed, high-volume Blow-Fill-Seal medical grade plastics technology and an interlocking Needle Hub, ApiJect can supply hundreds of millions of ultra-low-cost prefilled syringes with optional RFID tags to enable GPS-based mobile tracking. ApiJect, along with the U.S. Department of Health and Human Services, is a founding member of the RAPID Consortium, a public-private partnership dedicated to giving the U.S. and the world the surge drug packaging it needs for addressing future pandemics and bio-emergencies. Learn more about ApiJect at www.apiject.com.
RAPID USA, Inc., a subsidiary of ApiJect Systems America, Inc., is building and will manage the high-speed, high volume surge capacity for drug fill, finish and packaging that America needs to effectively respond to future pandemics and bio-emergencies. Starting in the second half of 2021, RAPID USA will begin rolling out new U.S.-based BFS drug packaging lines that once completed in 2022, will provide the capacity to fill and finish up to 330 million prefilled syringes per month for the U.S. and the world. The HHS-DOD emergency program, Project Jumpstart, to supply the U.S. with 100 million BFS prefilled syringes by year-end, is a RAPID USA initiative. Learn more at www.rapidconsortium.com.
The inventor of ApiJect, the first BFS injection device, is Marc Koska, one of the world’s most respected and successful social entrepreneurs. “At 23 years of age, Marc Koska was living an idyllic lifestyle as a self-confessed beach bum’, sailing yachts around the Caribbean and generally having a good time. And although he had always thought he was destined to do something big, it took a trip back to the UK in 1984 to tell him what that something would be.
“I saw an article in The Guardian predicting the transmission of HIV through the re-use of syringes. And I thought, that’s what I’ve been waiting for!” Doctors were re-using syringes, and people were being infected with wholly preventable diseases by people in which they had enormous faith. “It was a nightmare situation.” So there and then he designed and put together a disposable syringe, which would automatically disable after its first use. Fast-forward 17 years from that seminal moment in May 1984, and Koska sold his first syringe after which there was no stopping him: he’s since sold 700 million.
But it wasn’t easy. The big manufacturers didn’t want it to progress, he says, and the World Health Organisation in Geneva weren’t much help either. They ignored the 23-year-old “dipstick” with a vision of a safe injection policy. Did they even say they liked the idea? “I don’t know, they told me to bugger off!” he chuckles. He doesn’t believe the market was ready for the product back then; as he says, he had to remove 100 bricks from his path to get to the stage today where his company, Star Syringe, is the biggest Auto Disable (AD) syringe manufacturer in the world.” – Money Week, 2006
In 2005, MARC founded the SafePoint Trust charity NGO “to educate children about the dangers of employing used needles.” Kept living from little fundings, presentations and mainly trying to hit the jackpot selling vials.
In 2015, Chinese WHO director, Dr. Margaret Chan announced a new global policy on injection safety, promoting auto-disable-syringes and Marc’s set for life. The K-1 is now licensed and manufactured by 14 global manufacturers. His biography gets a glorious “upgrade” in the Guardian, he was no more a former “beach bum”, actually in 1984, he “was working in the Caribbean, building forensic models to support murder cases,”
Among many other honors bestowed on Mr. Koska, he was made an Officer of the Order of the British Empire for his “contribution to global healthcare”. From a “beach bum” to royal honors.
All sponsored by Bill Gates and US Government, the top donors to WHO’s budget.
Din any red light blink when I mentioned Marc Koska’s benefactor, “Chinese WHO director, Dr. Margaret Chan”? Yes friends, the wife of the Ministry of Foreign Affairs of the People’s Republic of China, Dr. David Chan was running WHO at the time and relaunching Marc’s career, after many years in which they ignored his intense lobbying. Should it be because of a little improvement added to the product design – the RFID chip?
A few words on Jay Walker, who leads ApiJect’s technology efforts, as well as its business and commercialization activities. He is best known as the founder of Priceline and curator of TEDMED. Yes, TED is ran by Pharma suits too, Bill Gates funded them and one more of their guys is in Apiject, alongside a former GlaxoSmithKlein executive and other Pharma troopers, according to their own website, already linked above. So, of course, TED platformed this business and you can find Koska speaking there in 2010.
A serial entrepreneur, Mr. Walker has founded three companies that have gone from launch to 50 million customers each. Mr. Walker is the world’s 10th most patented inventor, with more than 750 issued U.S. patents in technology-related fields.
Active in the field of medicine since 2012, Mr. Walker serves as chairman and curator of TEDMED, the health and medicine edition of the world-famous TED Conference. He is also Chairman of Upside, a travel and technology company that serves the unmanaged business traveler. A passionate student and practitioner of imagination, Mr. Walker founded and curated the Library of the History of Human Imagination, which Wired Magazine called, “the most amazing private library in the world.”
Bottom line: All the data collected by these RFID’s, the thermal scanning drones, the tracking, all the technological carnival around coronavirus and vaccines seems to be the actual agenda, not health, and it all needs 5G. This vaccination campaign proves to be more about data, surveillance and control, so 5G has to follow with it. US and China may fight on TV, but have collaborated on this at least since the times Fauci was funding Wuhan labs with American taxpayer money. They may have different propaganda shows on TV, but on the field US follows China’s footsteps with Chinese collaboration and know-how. WHO offered the “Umbrella Corporation” under which apparent enemies could collaborate for common population and resources control agendas.
A computer model developed in 1973 by a team of MIT researchers commissioned by the Club of Rome has predicted the “end of civilised life as we know it” by 2040, with a major change coming in 2020
The prediction came from a programme nicknamed World One, which was developed by a team of MIT researchers and processed by Australia’s largest computer.
It was originally devised by computer pioneer Jay Forrester, after he was tasked by the Club of Rome to develop a model of global sustainability.
However, the shocking result of the computer calculations showed that the level of pollution and population would cause a global collapse by 2040. The eerie calculation has been remarkably accurate in certain predictions, such as a stagnated quality of life and diminishing pool of natural resources. At this time the broadcasters addreses the audience: “At around 2020, the condition of the planet becomes highly critical. If we do nothing about it, the quality of life goes down to zero. Pollution becomes so seriously it will start to kill people, which in turn will cause the population to diminish, lower than it was in the 1900. At this stage, around 2040 to 2050, civilised life as we know it on this planet will cease to exist.”
Alexander King, a British pioneer who led the Club of Rome, also made a shocking prediction regarding national sovereignty. He told ABC:
“Sovereignty of nations is no longer absolute. There is a gradually diminishing of sovereignty, little bit by little bit. Even in the big nations, this will happen.”
#FlattenTheLies Face Mask by Silview MASKS ARE BAD FOR YOU, USE THEM ONLY IF YOU HAVE NO BETTER ALTERNATIVE! OR AT PROTESTS. AND IF YOU DO, USE ONE THAT SENDS OUT THE RIGHT MESSAGE.
World One, the computer program, looked at the world as one system. The report called it “an electronic guided tour of our behavior since 1900 and where that behavior will lead us.” The program produced graphs that showed what would happen to the planet decades into the future. It plotted statistics and forecasts for such variables as population, quality of life, the supply of natural resources, pollution, and more. Following the trend lines, one could see where the crises might take place.
As one measure to prevent catastrophe, the Club of Rome predicted some nations like the U.S. would have to cut back on their appetites for gobbling up the world’s resources. It hoped that in the future world, prestige would stem from “low consumption”—one fact that has so far not materialized. Currently, nine in ten people around the world breathe air that has high levels of pollution, according to data from the World Health Organization (WHO). The agency estimates that 7 million deaths each year can be attributed to pollution.
As always with widely publicised predictions, the main question to be solved is: Prediction, programming or predictive programming?